- Home
- GOF vs SRPT Comparison
GOF vs SRPT Comparison
Compare GOF & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GOF | SRPT |
|---|---|---|
| Founded | N/A | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.5B |
| IPO Year | 2006 | 2000 |
Fundamental Metrics
Financial Performance| Metric | GOF | SRPT |
|---|---|---|
| Price | $11.06 | $16.12 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 29 |
| Target Price | N/A | ★ $25.85 |
| AVG Volume (30 Days) | 1.4M | ★ 2.7M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.12 |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $10.54 | $10.42 |
| 52 Week High | $15.20 | $43.92 |
Technical Indicators
Market Signals| Indicator | GOF | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 33.45 |
| Support Level | $10.54 | $15.70 |
| Resistance Level | $11.61 | $19.62 |
| Average True Range (ATR) | 0.11 | 0.78 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 20.77 | 3.75 |
Price Performance
Historical ComparisonAbout GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.